The purpose of this study is to determine if doxycycline will reduce progression of emphysema
in people living with HIV.
The secondary objectives are to examine the effects of doxycycline on change in quantity of
emphysema, six minute walk distance, patient reported outcomes, ratio of forced expiratory
volume in 1 second and forced vital capacity. Secondary objectives will also describe the
safety and tolerability of doxycycline and determine if doxycycline is associated with
development of antibiotic-resistant bacterial infections.
This study is a phase II, multicenter, randomized, double-blinded, placebo-controlled
clinical trial in approximately 250 people living with HIV who have emphysema.
Eligible participants will be randomized in a 1:1 fashion to doxycycline or placebo.
Participants will receive 100 mg doxycycline orally or matched placebo twice a day for 72
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.